BRPI0608180A2 - ácidos nucléicos que se ligam à grelina - Google Patents

ácidos nucléicos que se ligam à grelina

Info

Publication number
BRPI0608180A2
BRPI0608180A2 BRPI0608180-0A BRPI0608180A BRPI0608180A2 BR PI0608180 A2 BRPI0608180 A2 BR PI0608180A2 BR PI0608180 A BRPI0608180 A BR PI0608180A BR PI0608180 A2 BRPI0608180 A2 BR PI0608180A2
Authority
BR
Brazil
Prior art keywords
extension
box
nucleic acids
ghrelin
bind
Prior art date
Application number
BRPI0608180-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dirk Eulberg
Christian Maasch
Steffen Helmling
Sven Klussmann
Florian Jarosch
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of BRPI0608180A2 publication Critical patent/BRPI0608180A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
BRPI0608180-0A 2005-04-08 2006-04-10 ácidos nucléicos que se ligam à grelina BRPI0608180A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08
PCT/EP2006/003276 WO2006108599A2 (en) 2005-04-08 2006-04-10 Ghrelin binding nucleic acids

Publications (1)

Publication Number Publication Date
BRPI0608180A2 true BRPI0608180A2 (pt) 2009-11-17

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608180-0A BRPI0608180A2 (pt) 2005-04-08 2006-04-10 ácidos nucléicos que se ligam à grelina

Country Status (24)

Country Link
US (2) US8101734B2 (ja)
EP (1) EP1866412A2 (ja)
JP (2) JP5308813B2 (ja)
KR (1) KR20080009072A (ja)
CN (1) CN101189337B (ja)
AP (1) AP2007004189A0 (ja)
AR (1) AR052741A1 (ja)
AU (1) AU2006233647A1 (ja)
BR (1) BRPI0608180A2 (ja)
CA (1) CA2605377A1 (ja)
CR (1) CR9423A (ja)
DO (1) DOP2006000085A (ja)
EA (1) EA200701901A1 (ja)
GB (1) GB2439673A (ja)
GT (1) GT200600137A (ja)
IL (1) IL186085A0 (ja)
MA (1) MA29384B1 (ja)
MX (1) MX2007012419A (ja)
NL (2) NL1031538C2 (ja)
PE (1) PE20061358A1 (ja)
TN (1) TNSN07375A1 (ja)
TW (1) TW200718781A (ja)
UY (1) UY29460A1 (ja)
WO (1) WO2006108599A2 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513041T1 (de) * 2002-08-01 2011-07-15 Noxxon Pharma Ag Ghrelin bindende nukleinsäuren
CN1894407A (zh) * 2003-11-10 2007-01-10 诺松制药股份公司 特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US9296810B2 (en) 2008-05-02 2016-03-29 Novartis Ag Fibronectin-based binding molecules and uses thereof
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
EP3706779B1 (en) 2017-11-10 2022-12-14 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
WO2020250923A1 (ja) * 2019-06-11 2020-12-17 味の素株式会社 ペプチド及びその用途
KR20220062488A (ko) 2019-06-12 2022-05-17 바이오엔테크 유에스 인크. 신생항원 조성물 및 이의 용도
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
CA2218083A1 (en) 1995-05-03 1996-11-07 Antonius Nicolaas Maria Schumacher Identification of enantiomeric ligands
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
ES2346640T4 (es) * 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
ATE513041T1 (de) 2002-08-01 2011-07-15 Noxxon Pharma Ag Ghrelin bindende nukleinsäuren
CN1894407A (zh) 2003-11-10 2007-01-10 诺松制药股份公司 特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
GB2439673A (en) 2008-01-02
US20060258607A1 (en) 2006-11-16
AR052741A1 (es) 2007-03-28
NL1033520A1 (nl) 2007-08-06
UY29460A1 (es) 2006-11-30
KR20080009072A (ko) 2008-01-24
TNSN07375A1 (fr) 2009-03-17
EP1866412A2 (en) 2007-12-19
CR9423A (es) 2007-12-17
CN101189337B (zh) 2013-11-06
WO2006108599A2 (en) 2006-10-19
WO2006108599A3 (en) 2007-02-15
US20120115937A1 (en) 2012-05-10
NL1033520C2 (nl) 2010-01-21
MA29384B1 (fr) 2008-04-01
AU2006233647A1 (en) 2006-10-19
AU2006233647A2 (en) 2008-04-17
JP5308813B2 (ja) 2013-10-09
NL1031538A1 (nl) 2006-10-10
GB0719489D0 (en) 2007-11-21
TW200718781A (en) 2007-05-16
CA2605377A1 (en) 2006-10-19
DOP2006000085A (es) 2006-11-15
GT200600137A (es) 2006-11-22
IL186085A0 (en) 2008-01-20
AP2007004189A0 (en) 2007-10-31
US8101734B2 (en) 2012-01-24
JP2013176372A (ja) 2013-09-09
JP2008534024A (ja) 2008-08-28
MX2007012419A (es) 2007-12-05
NL1031538C2 (nl) 2007-03-20
PE20061358A1 (es) 2007-01-13
EA200701901A1 (ru) 2008-04-28
CN101189337A (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
BRPI0608180A2 (pt) ácidos nucléicos que se ligam à grelina
BR0116033A (pt) Amplificação isotérmica de ácidos nucléicos sobre um suporte sólido
BRPI0520369A2 (pt) catalisador orgánico com compatibilidade intensificada de enzima
BRPI0313202A8 (pt) Formas adicionais para interferir com as moléculas de rna
IL190501A0 (en) Multicomponent nucleic acid enzymes and methods for their use
BR112021012401A2 (pt) Acetil-transferases inovadoras
HUP0203914A2 (en) High order nucleic acid based structures
BRPI0515752A (pt) processo para a preparação de dicloretos do àcido 3-haloftálico
FR2906532B1 (fr) Nouvel oligonucleotide marque
TH30062S1 (th) เบ้าหล่อคานคอนกรีต
DE60031262D1 (de) Menschliche promotoren des gaba b-rezeptors 1
TH80115S (th) อิฐบล็อก
TH22261S1 (th) อิฐบล็อค
TH77040S (th) อิฐบล็อค
TH22258S1 (th) อิฐบล็อค
TH22260S1 (th) อิฐบล็อค
TH77044S (th) อิฐบล็อค
TH22264S1 (th) อิฐบล็อค
TH22266S1 (th) อิฐบล็อค
TH22268S1 (th) อิฐบล็อค
TH22269S1 (th) อิฐบล็อค
TH22270S1 (th) อิฐบล็อค
TH22271S1 (th) อิฐบล็อค
TH22272S1 (th) อิฐบล็อค
TH22275S1 (th) อิฐบล็อค

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.